Skip to main content
Erschienen in:

25.09.2023 | Clinical trial

Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study

verfasst von: Filippo Pesapane, Luca Nicosia, Priyan Tantrige, Simone Schiaffino, Alessandro Liguori, Marta Montesano, Anna Bozzini, Anna Rotili, Michaela Cellina, Marcello Orsi, Silvia Penco, Maria Pizzamiglio, Gianpaolo Carrafiello, Enrico Cassano

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Breast magnetic resonance imaging (MRI) and contrast-enhanced mammography (CEM) are nowadays used in breast imaging but studies about their inter-reader agreement are lacking. Therefore, we compared the inter-reader agreement of CEM and MRI in breast cancer diagnosis in the same patients.

Methods

Breast MRI and CEM exams performed in a single center (09/2020–09/2021) for an IRB-approved study were retrospectively and independently evaluated by four radiologists of two different centers with different levels of experience who were blinded to the clinical and other imaging data. The reference standard was the histological diagnosis or at least 1-year negative imaging follow-up. Inter-reader agreement was examined using Cohen’s and Fleiss’ kappa (κ) statistics and compared with the Wald test.

Results

Of the 750 patients, 395 met inclusion criteria (44.5 ± 14 years old), with 752 breasts available for CEM and MRI. Overall agreement was moderate (κ = 0.60) for MRI and substantial (κ = 0.74) for CEM. For expert readers, the agreement was substantial (κ = 0.77) for MRI and almost perfect (κ = 0.82) for CEM; for non-expert readers was fair (κ = 0.39); and for MRI and moderate (κ = 0.57) for CEM. Pairwise agreement between expert readers and non-expert readers was moderate (κ = 0.50) for breast MRI and substantial (κ = 0.74) for CEM and it showed a statistically superior agreement of the expert over the non-expert readers only for MRI (p = 0.011) and not for CEM (p = 0.062).

Conclusions

The agreement of CEM was superior to that of MRI (p = 0.012), including for both expert (p = 0.031) and non-expert readers (p = 0.005).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tan W, Yang M, Yang H, Zhou F, Shen W (2018) Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res 10:4333–4347CrossRefPubMedPubMedCentral Tan W, Yang M, Yang H, Zhou F, Shen W (2018) Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res 10:4333–4347CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Dogan BE, Scoggins ME, Son JB et al (2018) American college of radiology-compliant short protocol breast mri for high-risk breast cancer screening: a prospective feasibility study. AJR Am J Roentgenol 210:214–221CrossRefPubMed Dogan BE, Scoggins ME, Son JB et al (2018) American college of radiology-compliant short protocol breast mri for high-risk breast cancer screening: a prospective feasibility study. AJR Am J Roentgenol 210:214–221CrossRefPubMed
4.
Zurück zum Zitat McGrath AL, Price ER, Eby PR, Rahbar H (2017) MRI-guided breast interventions. J Magn Reson Imaging 46:631–645CrossRefPubMed McGrath AL, Price ER, Eby PR, Rahbar H (2017) MRI-guided breast interventions. J Magn Reson Imaging 46:631–645CrossRefPubMed
5.
Zurück zum Zitat Kuhl CK (2016) The changing world of breast cancer: a radiologist’s perspective. Plast Surg Nurs 36:31–49CrossRefPubMed Kuhl CK (2016) The changing world of breast cancer: a radiologist’s perspective. Plast Surg Nurs 36:31–49CrossRefPubMed
8.
Zurück zum Zitat Penco S, Rotili A, Pesapane F et al (2020) MRI-guided vacuum-assisted breast biopsy: experience of a single tertiary referral cancer centre and prospects for the future. Med Oncol 37:36CrossRefPubMed Penco S, Rotili A, Pesapane F et al (2020) MRI-guided vacuum-assisted breast biopsy: experience of a single tertiary referral cancer centre and prospects for the future. Med Oncol 37:36CrossRefPubMed
9.
Zurück zum Zitat Pesapane F, Suter MB, Rotili A et al (2020) Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? Med Oncol 37:29CrossRefPubMed Pesapane F, Suter MB, Rotili A et al (2020) Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? Med Oncol 37:29CrossRefPubMed
10.
Zurück zum Zitat Fallenberg EM, Schmitzberger FF, Amer H et al (2017) Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation. Eur Radiol 27:2752–2764CrossRefPubMed Fallenberg EM, Schmitzberger FF, Amer H et al (2017) Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation. Eur Radiol 27:2752–2764CrossRefPubMed
11.
Zurück zum Zitat Daniaux M, Gruber L, De Zordo T et al (2023) Preoperative staging by multimodal imaging in newly diagnosed breast cancer: Diagnostic performance of contrast-enhanced spectral mammography compared to conventional mammography, ultrasound, and MRI. Eur J Radiol 163:110838CrossRefPubMed Daniaux M, Gruber L, De Zordo T et al (2023) Preoperative staging by multimodal imaging in newly diagnosed breast cancer: Diagnostic performance of contrast-enhanced spectral mammography compared to conventional mammography, ultrasound, and MRI. Eur J Radiol 163:110838CrossRefPubMed
12.
Zurück zum Zitat Potsch N, Vatteroni G, Clauser P, Helbich TH, Baltzer PAT (2022) Contrast-enhanced mammography versus contrast-enhanced breast mri: a systematic review and meta-analysis. Radiology 305:94–103CrossRefPubMed Potsch N, Vatteroni G, Clauser P, Helbich TH, Baltzer PAT (2022) Contrast-enhanced mammography versus contrast-enhanced breast mri: a systematic review and meta-analysis. Radiology 305:94–103CrossRefPubMed
13.
Zurück zum Zitat Gelardi F, Ragaini EM, Sollini M, Bernardi D, Chiti A (2022) Contrast-enhanced mammography versus breast magnetic resonance imaging: a systematic review and meta-analysis. Diagnostics 12(8):1890CrossRefPubMedPubMedCentral Gelardi F, Ragaini EM, Sollini M, Bernardi D, Chiti A (2022) Contrast-enhanced mammography versus breast magnetic resonance imaging: a systematic review and meta-analysis. Diagnostics 12(8):1890CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Jochelson MS, Lobbes MBI (2021) Contrast-enhanced Mammography: state of the Art. Radiology 299:36–48CrossRefPubMed Jochelson MS, Lobbes MBI (2021) Contrast-enhanced Mammography: state of the Art. Radiology 299:36–48CrossRefPubMed
15.
Zurück zum Zitat Gennaro G, Cozzi A, Schiaffino S, Sardanelli F, Caumo F (2022) Radiation dose of contrast-enhanced mammography: a two-center prospective comparison. Cancers 14(7):1774CrossRefPubMedPubMedCentral Gennaro G, Cozzi A, Schiaffino S, Sardanelli F, Caumo F (2022) Radiation dose of contrast-enhanced mammography: a two-center prospective comparison. Cancers 14(7):1774CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Baltzer PAT, Bickel H, Spick C et al (2018) Potential of noncontrast magnetic resonance imaging with diffusion-weighted imaging in characterization of breast lesions: intraindividual comparison with dynamic contrast-enhanced magnetic resonance imaging. Invest Radiol 53:229–235CrossRefPubMedPubMedCentral Baltzer PAT, Bickel H, Spick C et al (2018) Potential of noncontrast magnetic resonance imaging with diffusion-weighted imaging in characterization of breast lesions: intraindividual comparison with dynamic contrast-enhanced magnetic resonance imaging. Invest Radiol 53:229–235CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Pesapane F, Rotili A, Penco S et al (2021) Inter-reader agreement of diffusion-weighted magnetic resonance imaging for breast cancer detection: a multi-reader retrospective study. Cancers 13(8):1978CrossRefPubMedPubMedCentral Pesapane F, Rotili A, Penco S et al (2021) Inter-reader agreement of diffusion-weighted magnetic resonance imaging for breast cancer detection: a multi-reader retrospective study. Cancers 13(8):1978CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Dromain C, Thibault F, Diekmann F et al (2012) Dual-energy contrast-enhanced digital mammography: initial clinical results of a multireader, multicase study. Breast Cancer Res 14:R94CrossRefPubMedPubMedCentral Dromain C, Thibault F, Diekmann F et al (2012) Dual-energy contrast-enhanced digital mammography: initial clinical results of a multireader, multicase study. Breast Cancer Res 14:R94CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Lobbes MB, Lalji U, Houwers J et al (2014) Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme. Eur Radiol 24:1668–1676PubMed Lobbes MB, Lalji U, Houwers J et al (2014) Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme. Eur Radiol 24:1668–1676PubMed
20.
Zurück zum Zitat D’Orsi CJ SE, Mendelson EB, Morris EA, et al., (2013) ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System, V edition edn. American College of Radiology D’Orsi CJ SE, Mendelson EB, Morris EA, et al., (2013) ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System, V edition edn. American College of Radiology
21.
Zurück zum Zitat American College of Radiology (ACR) (2003) BIRADS-MRI. Breast imaging reporting and data system atlas. American College of Radiology American College of Radiology (ACR) (2003) BIRADS-MRI. Breast imaging reporting and data system atlas. American College of Radiology
23.
Zurück zum Zitat Lobbes MB, Lalji UC, Nelemans PJ et al (2015) The quality of tumor size assessment by contrast-enhanced spectral mammography and the benefit of additional breast MRI. J Cancer 6:144–150CrossRefPubMedPubMedCentral Lobbes MB, Lalji UC, Nelemans PJ et al (2015) The quality of tumor size assessment by contrast-enhanced spectral mammography and the benefit of additional breast MRI. J Cancer 6:144–150CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Landis JR, Koch GG (1977) An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 33:363–374CrossRefPubMed Landis JR, Koch GG (1977) An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 33:363–374CrossRefPubMed
25.
Zurück zum Zitat Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37–46CrossRef Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37–46CrossRef
26.
Zurück zum Zitat Antognini AB, Vagheggini A, Zagoraiou M (2018) Is the classical Wald test always suitable under response-adaptive randomization? Stat Methods Med Res 27:2294–2311CrossRefPubMed Antognini AB, Vagheggini A, Zagoraiou M (2018) Is the classical Wald test always suitable under response-adaptive randomization? Stat Methods Med Res 27:2294–2311CrossRefPubMed
28.
Zurück zum Zitat Mann RM, Athanasiou A, Baltzer PAT et al (2022) Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol 32:4036–4045CrossRefPubMedPubMedCentral Mann RM, Athanasiou A, Baltzer PAT et al (2022) Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol 32:4036–4045CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Nicosia L, Bozzini AC, Palma S et al (2022) Contrast-Enhanced Spectral Mammography and tumor size assessment: a valuable tool for appropriate surgical management of breast lesions. Radiol Med 127:1228–1234CrossRefPubMed Nicosia L, Bozzini AC, Palma S et al (2022) Contrast-Enhanced Spectral Mammography and tumor size assessment: a valuable tool for appropriate surgical management of breast lesions. Radiol Med 127:1228–1234CrossRefPubMed
30.
Zurück zum Zitat Pesapane F, Agazzi GM, Rotili A et al (2022) Prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients with MRI-radiomics: a systematic review and meta-analysis. Curr Probl Cancer 46:100883CrossRefPubMed Pesapane F, Agazzi GM, Rotili A et al (2022) Prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients with MRI-radiomics: a systematic review and meta-analysis. Curr Probl Cancer 46:100883CrossRefPubMed
31.
Zurück zum Zitat Xiang W, Rao H, Zhou L (2020) A meta-analysis of contrast-enhanced spectral mammography versus MRI in the diagnosis of breast cancer. Thorac Cancer 11:1423–1432CrossRefPubMedPubMedCentral Xiang W, Rao H, Zhou L (2020) A meta-analysis of contrast-enhanced spectral mammography versus MRI in the diagnosis of breast cancer. Thorac Cancer 11:1423–1432CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Houssami N, Turner R, Morrow M (2013) Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg 257:249–255CrossRefPubMed Houssami N, Turner R, Morrow M (2013) Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg 257:249–255CrossRefPubMed
33.
Zurück zum Zitat Suter MB, Pesapane F, Agazzi GM et al (2020) Diagnostic accuracy of contrast-enhanced spectral mammography for breast lesions: a systematic review and meta-analysis. Breast 53:8–17CrossRefPubMedPubMedCentral Suter MB, Pesapane F, Agazzi GM et al (2020) Diagnostic accuracy of contrast-enhanced spectral mammography for breast lesions: a systematic review and meta-analysis. Breast 53:8–17CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Tagliafico AS, Bignotti B, Rossi F et al (2016) diagnostic performance of contrast-enhanced spectral mammography: systematic review and meta-analysis. Breast 28:13–19CrossRefPubMed Tagliafico AS, Bignotti B, Rossi F et al (2016) diagnostic performance of contrast-enhanced spectral mammography: systematic review and meta-analysis. Breast 28:13–19CrossRefPubMed
35.
Zurück zum Zitat Cozzi A, Magni V, Zanardo M, Schiaffino S, Sardanelli F (2022) Contrast-enhanced mammography: a systematic review and meta-analysis of diagnostic performance. Radiology 302:568–581CrossRefPubMed Cozzi A, Magni V, Zanardo M, Schiaffino S, Sardanelli F (2022) Contrast-enhanced mammography: a systematic review and meta-analysis of diagnostic performance. Radiology 302:568–581CrossRefPubMed
36.
Zurück zum Zitat Neeter LMFHRM, van Nijnatten TJA, Jochelson MS, Raat HPJ, Wildberger JE, Smidt ML, Nelemans PJ, Lobbes MBI (2023) Comparing the diagnostic performance of contrast-enhanced mammography and breast MRI: a systematic review and meta-analysis. J Cancer 14:174–182CrossRefPubMedPubMedCentral Neeter LMFHRM, van Nijnatten TJA, Jochelson MS, Raat HPJ, Wildberger JE, Smidt ML, Nelemans PJ, Lobbes MBI (2023) Comparing the diagnostic performance of contrast-enhanced mammography and breast MRI: a systematic review and meta-analysis. J Cancer 14:174–182CrossRefPubMedPubMedCentral
37.
38.
Zurück zum Zitat Warner E, Causer PA, Wong JW et al (2011) Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J 17:9–17CrossRefPubMed Warner E, Causer PA, Wong JW et al (2011) Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J 17:9–17CrossRefPubMed
Metadaten
Titel
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study
verfasst von
Filippo Pesapane
Luca Nicosia
Priyan Tantrige
Simone Schiaffino
Alessandro Liguori
Marta Montesano
Anna Bozzini
Anna Rotili
Michaela Cellina
Marcello Orsi
Silvia Penco
Maria Pizzamiglio
Gianpaolo Carrafiello
Enrico Cassano
Publikationsdatum
25.09.2023
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2023
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-023-07093-w

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.